Investigational Drug Information for Bemcentinib
✉ Email this page to a colleague
What is the drug development status for Bemcentinib?
Bemcentinib is an investigational drug.
There have been 10 clinical trials for Bemcentinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 17th 2017.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Preleukemia. The leading clinical trial sponsors are BerGenBio ASA, Merck Sharp & Dohme Corp., and BerGenBio AS.
There are thirteen US patents protecting this investigational drug and two hundred and thirty-five international patents.
Summary for Bemcentinib
| US Patents | 13 |
| International Patents | 235 |
| US Patent Applications | 142 |
| WIPO Patent Applications | 122 |
| Japanese Patent Applications | 19 |
| Clinical Trial Progress | Phase 2 (2017-10-17) |
| Vendors | 60 |
Recent Clinical Trials for Bemcentinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer | BerGenBio ASA | Phase 1/Phase 2 |
| A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients | BerGenBio ASA | Phase 2 |
| AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | BerGenBio ASA | Early Phase 1 |
Clinical Trial Summary for Bemcentinib
Top disease conditions for Bemcentinib
Top clinical trial sponsors for Bemcentinib
US Patents for Bemcentinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bemcentinib | ⤷ Try a Trial | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | Anti-Axl antagonistic antibodies | BERGEN TEKNOLOGIOVERFORING AS (Bergen, NO) BERGEBIO ASA (Bergen, NO) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | Methods of detecting Akt3 and administering Ax1 inhibitor | BERGENBIO ASA (Bergen, NO) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | Pharmaceutically active compounds | BerGenBio ASA (Bergen, NO) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | Combination therapy with an anti-axl antibody-drug conjugate | ADC THERAPEUTICS SA (Epalinges, CH) MEDIMMUNE LIMTIED (Cambridge, GB) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | Heterocyclic compounds and uses thereof | Infinity Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Try a Trial |
| Bemcentinib | ⤷ Try a Trial | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bemcentinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bemcentinib | Australia | AU2016322552 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | Canada | CA2998469 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | China | CN108349985 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | China | CN114230571 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | European Patent Office | EP3350183 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | Hong Kong | HK1261923 | 2035-09-14 | ⤷ Try a Trial |
| Bemcentinib | Israel | IL258052 | 2035-09-14 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
